Effect of niridazole and niridazole immunoregulatory factor (NIF) on cutaneous delayed hypersensitivity in mice.
It has been suggested that the suppression of cell-mediated immune phenomena following niridazole administration is most likely due to a niridazole metabolite rather than the parent drug. This hypothesis was tested using two inbred strains of mice that manifest different rates of microsomal niridazole oxidation and reduction. DBA/2J mice were found to metabolize niridazole at a rate approximately 3-fold greater than C57BL/6J mice under both aerobic and anaerobic conditions. Niridazole was found to be more potent with respect to suppression of cutaneous delayed hypersensitivity in the former than in the latter. An immunosuppressive component was isolated from the urine fraction obtained from niridazole-treated rats. This component was found to be chromatographically pure; have a simple UV absorbance spectrum containing no 360 nm absorbing material characteristic of niridazole; to show no strain difference with respect to potency or efficacy in the ear-swelling assay for cutaneous delayed hypersensitivity; and to be 10(7) times more potent than niridazole with respect to the suppression of cutaneous delayed hypersensitivity.
D000818:Animals; D001688:Biological Products / Q000494:pharmacology* / Q000652:urine; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy*; D007108:Immune Tolerance; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL / Q000378:metabolism*; D008811:Mice, Inbred DBA / Q000378:metabolism*; D008862:Microsomes, Liver / Q000378:metabolism; D009560:Niridazole / Q000378:metabolism / Q000494:pharmacology* / Q000652:urine; D051381:Rats
D001688:Biological Products; D009560:Niridazole